Clinical Trials with Immunotoxins

$0Z01FY2004BCNIH

Basic Sciences

Investigators

Linked publications & trials

Paper 18678888 Paper 18676854 Paper 18403491 Paper 17671130 Paper 17435179 Paper 17312057 Paper 17297371 Paper 16857795 Paper 16681430 Paper 16675574 Paper 16638849 Paper 16428485 Paper 16311729 Paper 16082249 Paper 16061911 Paper 15701286 Paper 15217923 Paper 14734446 Paper 14649883

Abstract

A phase 2 trial with immunotoxin BL22 that targets B cell malignancies has been opened in patients with Hairy Cell Leukemia. So far eight patients have been treated and seven have shown a complete hematologic remission. A phase 1 trial with BL22 in pediatric ALL was opened in collaboration with Dr. Alan Wayne, P.O.B. The current dose level is 25 ug/kg Q.O.D. x 3. No major toxicities have occurred. Two phase 1 trials with immunotoxin SS1P in mesothelioma, pancreatic cancer and ovarian cancer are open. Several minor responses were observed. Dose escalation is continuing. A phase 1 trial with immunotoxin LMB 2 targeting CD25 has been opened and 3 patients treated, and a phase 1 trial in CTCL is now open for accrual.

View original record on NIH RePORTER →